UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response

Clinical pharmacology and therapeutics, 2008-01, Vol.83 (1), p.160-166

2008

Volltextzugriff (PDF)

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

JAMA : the journal of the American Medical Association, 2009-10, Vol.302 (13), p.1429

2009

Volltextzugriff (PDF)

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

Journal of clinical oncology, 2005-12, Vol.23 (36), p.9312-9318

2005

Volltextzugriff (PDF)

Identification of a Notch transcriptomic signature for breast cancer

Breast cancer research : BCR, 2024-01, Vol.26 (1), p.4-4, Article 4

2024

Volltextzugriff (PDF)

Abstract P5-04-05: Glucocorticoid receptor activation inhibits proliferation of endoxifen resistant breast cancer cells and resensitizes cells to hormonal therapy

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-04-05

2019

Volltextzugriff (PDF)

A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy

Breast cancer research and treatment, 2021-08, Vol.189 (1), p.15-23

2021

Volltextzugriff (PDF)

The Hsp90 chaperone complex as a novel target for cancer therapy

Annals of oncology, 2003-08, Vol.14 (8), p.1169-1176

2003

Volltextzugriff (PDF)

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer

Journal of clinical oncology, 2005-02, Vol.23 (6), p.1078-1087

2005

Volltextzugriff (PDF)

CYP2D6 Genotype and Tamoxifen: Considerations for Proper Nonprospective Studies

Clinical pharmacology and therapeutics, 2014-08, Vol.96 (2), p.141-144

2014

Volltextzugriff (PDF)

Abstract P5-11-11: A preliminary assessment of knowledge, attitudes, and awareness surrounding ESR1 mutations and biomarker testing amongst medical oncologists

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P5-P5-11-11

2019

Volltextzugriff (PDF)

Abstract P3-08-09: The 21-gene recurrence score and chemotherapy use in triple negative breast cancer (TNBC) and HER2 positive breast cancer: A National Cancer Database study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-08-09

2019

Volltextzugriff (PDF)

Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)

Breast cancer research and treatment, 2018-05, Vol.169 (1), p.1-7

2018

Volltextzugriff (PDF)

Percutaneous Image-Guided Radiofrequency Ablation of Painful Metastases Involving Bone: A Multicenter Study

Journal of clinical oncology, 2004-01, Vol.22 (2), p.300-306

2004

Volltextzugriff (PDF)

Abstract P5-04-04: Activation of ERβ in triple negative breast cancer results in cell cycle arrest

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P5-P5-04-04

2017

Volltextzugriff (PDF)

Abstract P5-07-01: LncRNA MIR2052HG regulates ERα level and endocrine resistance through LMTK3 by recruiting early growth response protein 1

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-07-01

2018

Volltextzugriff (PDF)

Abstract GS6-02: The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.GS6-02-GS6-02

2018

Volltextzugriff (PDF)

Abstract P2-07-05: A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P2-P2-07-05

2019

Volltextzugriff (PDF)

Abstract OT1-01-02: An open-label, randomized, multi-center phase 2 study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic ER+/HER2 - breast cancer (MBC) with an ESR1 mutation

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT1-01-02-OT1-01-02

2019

Volltextzugriff (PDF)

Abstract P6-16-01: Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2- advanced breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-16-01

2019

Volltextzugriff (PDF)

A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen

Clinical cancer research, 2006-04, Vol.12 (7), p.2080-2087

2006

Volltextzugriff (PDF)

Abstract P1-03-04: Molecular subtyping of androgen receptor-positive patients using gene expression profiles

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P1-P1-03-04

2019

Volltextzugriff (PDF)

Abstract OT3-02-08: Genetic analysis in blood, urine, stool and tumor samples from patients with advanced or metastatic estrogen receptor positive and HER2 negative breast cancer receiving palbociclib and endocrine therapy (PROMISE)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-02-08-OT3-02-08

2019

Volltextzugriff (PDF)

Abstract P6-18-09: Clinical management of metastatic breast cancer (MBC) after CDK 4/6 inhibitors: A retrospective single-institution study

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-18-09

2019

Volltextzugriff (PDF)

Abstract P3-06-10: Multiscale modeling of omics data for precision breast cancer treatment

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P3-P3-06-10

2019

Volltextzugriff (PDF)

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-02-07-OT3-02-07

2019

Volltextzugriff (PDF)

1 – 25 von 81

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(75)

Publikationsform

Sprache

Englisch
(81)

Erscheinungsjahr

n.n

Thema

Science & Technology
(37)
Life Sciences & Biomedicine
(32)
Humans
(26)
Female
(22)
Biological And Medical Sciences
(16)
Medical Sciences
(16)
Male
(13)
Oncology
(11)
Middle Aged
(10)
Adult
(9)
Aged
(9)
Breast Neoplasms - Drug Therapy
(9)
Breast Neoplasms - Genetics
(7)
Pharmacology. Drug Treatments
(7)
Antineoplastic Agents, Hormonal - Therapeutic Use
(6)
Breast Cancer
(6)
Clinical Neurology
(6)
Genotype
(6)
Neoplasms - Drug Therapy
(6)
Neurosciences & Neurology
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tamoxifen Pharmacogenomics: The Role of CYP2D6 as a Predictor of Drug Response

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

Identification of a Notch transcriptomic signature for breast cancer

Abstract P5-04-05: Glucocorticoid receptor activation inhibits proliferation of endoxifen resistant breast cancer cells and resensitizes cells to hormonal therapy

A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy

The Hsp90 chaperone complex as a novel target for cancer therapy

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer

CYP2D6 Genotype and Tamoxifen: Considerations for Proper Nonprospective Studies

Abstract P5-11-11: A preliminary assessment of knowledge, attitudes, and awareness surrounding ESR1 mutations and biomarker testing amongst medical oncologists

Abstract P3-08-09: The 21-gene recurrence score and chemotherapy use in triple negative breast cancer (TNBC) and HER2 positive breast cancer: A National Cancer Database study

Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)

Percutaneous Image-Guided Radiofrequency Ablation of Painful Metastases Involving Bone: A Multicenter Study

Abstract P5-04-04: Activation of ERβ in triple negative breast cancer results in cell cycle arrest

Abstract P5-07-01: LncRNA MIR2052HG regulates ERα level and endocrine resistance through LMTK3 by recruiting early growth response protein 1

Abstract GS6-02: The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies

Abstract P2-07-05: A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced stage breast cancer treated with first-line endocrine therapy

Abstract OT1-01-02: An open-label, randomized, multi-center phase 2 study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic ER+/HER2 - breast cancer (MBC) with an ESR1 mutation

Abstract P6-16-01: Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2- advanced breast cancer

A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen

Abstract P1-03-04: Molecular subtyping of androgen receptor-positive patients using gene expression profiles

Abstract OT3-02-08: Genetic analysis in blood, urine, stool and tumor samples from patients with advanced or metastatic estrogen receptor positive and HER2 negative breast cancer receiving palbociclib and endocrine therapy (PROMISE)

Abstract P6-18-09: Clinical management of metastatic breast cancer (MBC) after CDK 4/6 inhibitors: A retrospective single-institution study

Abstract P3-06-10: Multiscale modeling of omics data for precision breast cancer treatment

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Suchergebnisse filtern